Trial · NCT04523792
Virginia Opioid Treatment-Emergency Department
NCT04523792, Phase 3, Withdrawn, Virginia Commonwealth University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Virginia Opioid Treatment-Emergency Department. Trials, record NCT04523792. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04523792
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Virginia Opioid Treatment-Emergency Department
- NCT number
- NCT04523792
- Status
- Withdrawn
- Phases
- Phase 3
- Enrollment
- 0 participants, actual
- Lead sponsor
- Virginia Commonwealth University
- Conditions
- Opioid Use Disorder
- Interventions
- SUBLOCADE
- First posted
- 2020-08-24
- Last updated
- 2021-02-12
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment engagement - 1 month | 1 month | Treatment engagement as measured by percentage of participants who attend an outpatient clinic visit within 1 month of first injection. |
| Secondary | Treatment engagement - 3 and 6 months | 3 and 6 months | Treatment engagement as measured by percentage of participants who continue to attend outpatient clinic visits with SUBLOCADE injections (buprenorphine treatment) at 3 and 6 months. |
| Secondary | Number of repeat ED visits | 6 months | Number of repeat ED visits for any reason will be measured from electronic medical records and self-reported data. |
| Other | Healthcare resource utilization | 6 months | Healthcare resource utilization (measured by number of outpatient clinic and emergency department visits, and number of inpatient admissions) as compared to the concurrent and historical control groups. |
| Other | Opioid craving | 6 months | Opioid craving in subjects as measured by Craving Visual Analog Scale (VAS), a 3-item scale in which individuals rate their cravings for opioids on a scale from 0 (NOT AT ALL) to 10 (EXTREMELY). |
| Other | Number of participants with a urine drug screen negative for illicit opioids. | 6 months | Illicit opioid use as measured by urine drug screen (UDS) results. |
| Other | Impulse control | 6 months | Time to decision in delay discounting task |
| Other | Opioid cravings | 6 months | Brief opioid demand task |
| Other | Number of non-fatal or fatal opioid-related overdoses | 6 months | Data on the number of opioid overdoses will be measured from electronic medical records and/or state death registries. |
| Other | Treatment effectiveness: Treatment Effectiveness Assessment (TEA) | 6 months | Treatment effectiveness as measured by Treatment Effectiveness Assessment (TEA), which measures on 4 domains (substance use, health, lifestyle, community involvement). Responses on each item range from 1 ("not better at all") to 10 ("very much better") with items summed for a total score of 4-40, and higher scores reflecting greater self-report of treatment effectiveness. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Delay Discounting | Other outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04523792
GET https://conductscience.org/api/trials/v1/NCT04523792/registered